Medical Microbiology articles for Spain

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 56

Article ‘Count’ for Medical Microbiology.

Journal Count Share
1 0.06
The ATM Kinase Inhibitor AZD0156 Is a Potent Inhibitor of iPlasmodium/i Phosphatidylinositol 4‐Kinase (PI4Kβ) and Is an Attractive Candidate for Medicinal Chemistry Optimization Against Malaria 0.06
2 0.27
Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections 0.05
Structural basis of poxvirus fusion regulation and anti-A16/G9 antibody-mediated neutralization and protection 0.22
1 0.03
Coronavirus protein interaction mapping in bat and human cells reveals network rewiring governing immune evasion and zoonotic potential 0.03
1 0.23
Pseudomonas aeruginosa in patients with Nosocomial Respiratory Infections: A secondary analysis of the European Network for ICU-Related Respiratory Infections (ENIRRIs). 0.23
9 3.78
Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial 0.04
Predictors of Treatment Failure in Children Living With HIV Starting First-line Antiretroviral Therapy in the ODYSSEY Trial 0.04
Burden of Respiratory Syncytial Virus Among Older Adults With an Acute Respiratory Infection: A Prospective Study in Six European Countries 0.33
Health-related Quality of Life in European Older Adults with Respiratory Syncytial Virus Over Three Respiratory Syncytial Virus Seasons 0.27
Respiratory Syncytial Virus After CAR T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort 0.05
Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles 1.00
Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country 1.00
Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002–2023) 1.00
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients with COVID-19 (BIRCH): a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study 0.04
5 0.72
Tracking B cell immunity during perturbation of hepatitis B infection induced by treatment withdrawal 0.48
HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER) 0.11
Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT study 0.07
Helicobacter pylori antibiotic resistance: a global challenge in search of solutions 0.03
Differential HCC risk among HBV indeterminate types at baseline and by phase transition 0.03
1 0.19
Type I interferon autoantibody footprints reveal neutralizing mechanisms and allow inhibitory decoy design 0.19
3 0.25
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares 0.11
Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B – follow-up from the RETRACT-B cohort 0.06
A phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C 0.08
5 1.23
Comparison of Healthcare Resource Utilization and Disease Outcomes in Adults Hospitalized with Human Metapneumovirus and Respiratory Syncytial Virus 0.06
Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration 1.00
Leptospirosis Prevalence and Risk Factors Among Patients Presenting With Fever to 4 Healthcare Sites in Sub-Saharan Africa and South East Asia: An International Multisite Observational and Nested Case–Control Study 0.05
Artemether-Lumefantrine Treatment Selects Plasmodium falciparum Multidrug Resistance 1 (pfmdr1) Increased Copy Number Among African Malaria Infections 0.03
The Choice of Viral Load End Point in Early Phase Trials of COVID-19 Treatments Aiming to Reduce 28-Day Hospitalization and/or Death 0.09
1 0.02
Targeting de novo purine biosynthesis for tuberculosis treatment 0.02
11 1.96
Alpibectir–Ethionamide combination (AlpE) for the treatment of tuberculosis 0.16
Collateral hypersensitivity between ZY19489 and piperaquine neutralizes PfCRT-mediated drug efflux and Plasmodium falciparum resistance 0.07
’s lifestyle includes soil-dwelling colonization of decaying plant material and airborne spread 0.06
Pangenome dynamics and population structure of the zoonotic pathogen Salmonella enterica serotype Hadar 0.15
Insights into the self-assembly and interaction of sars-cov-2 fusion peptides with biomimetic plasma membranes 0.50
Highly replicating hepatitis C virus variants emerge in immunosuppressed patients causing severe disease 0.04
The role of cytochrome bc1 inhibitors in future tuberculosis treatment regimens 0.08
Effect of intrapartum azithromycin on early childhood gut mycobiota development: post hoc analysis of a double-blind randomized trial 0.06
Global dissemination of npmA mediated pan-aminoglycoside resistance via a mobile genetic element in Gram-positive bacteria 0.50
Respiratory syncytial virus hospitalisation by chronological month of age and by birth month in infants 0.01
Ciprofloxacin resistance rapidly declines in nfxB defective clinical strains of Pseudomonas aeruginosa 0.33
1 0.02
Antibiotic use and gut microbiome composition links from individual-level prescription data of 14,979 individuals 0.02
1 1.00
Translational repression of viral RNAs supports persistent arbovirus infection in mosquitoes 1.00
1 1.00
The actin module of endocytic internalization in Aspergillus nidulans: A critical role of the WISH/DIP/SPIN90 family protein Dip1 1.00
2 1.50
LUCID: An Integrative Approach for Target Discovery and dsRNA Design in Plant Fungal Pathogens 1.00
S2-PepAnalyst: A Web Tool for Predicting Plant Small Signalling Peptides 0.50
3 2.09
SARS-CoV-2 mutant spectrum complexity is an epidemiologically evolvable trait 0.93
SARS-CoV-2-derived RNA replicons as safe and effective vaccines 0.96
Quantifying phage infectivity from characteristics of bacterial population dynamics 0.20
1 0.06
Pan-viral ORFs discovery using massively parallel ribosome profiling 0.06
3 0.60
Fungal infection drives metabolic reprogramming in epithelial cells via aerobic glycolysis and an alternative TCA cycle shunt 0.07
Structures of Vibrio cholerae transcription complexes reveal how ToxR and TcpP recruit the RNA polymerase and activate virulence genes 0.50
Broad-spectrum synthetic carbohydrate receptors (SCRs) inhibit viral entry across multiple virus families 0.03
1 1.00
Structural insights into the antibacterial function of the effector Tke5 1.00
1 0.14
Everything is everywhere but Escherichia coli adapts to different niches 0.14
1 0.12
Regional and type-specific variations in the global seasonality of human parainfluenza viruses and the influence of climatic factors: a systematic review and meta-analysis 0.12
1 0.02
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection 0.02

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.